First Patient Dosed in Optimize-1 Phase II
"We continued to make great strides in the third quarter of 2021. The first patient was dosed in OPTIMIZE-1, our clinical Phase II study, that will assess the effect of mitazalimab in first line pancreatic cancer. We entered a collaboration with Finnish based
Søren Bregenholt
CEO
Significant Events: July -
-
New Senior Director of Communications and Investor Relations,
Julie Silber , joined the Company, bringing a unique experience fromWall Street and 20+ years of investor relations, strategic communications, counsel, and executive financial leadership.
-
The Company entered into a research collaboration and license agreement with
Orion Corporation , a global pharmaceutical company based inFinland , to discover and develop new immuno-oncology product candidates.
-
The Company announced that it is exploring financing alternatives to support phase II studies for Mitazalimab, phase II preparations for ATOR-1017, as well as the development of other pipeline assets.
-
The Company announced positive results from our collaboration with
Scandion Oncology (Sweden ) exploring the anti-tumor efficacy of the CD40 antibody mitazalimab in chemotherapy-resistant preclinical tumor models as an addition to chemotherapy (FOLFIRINOX).
-
The Company announced first patient dosed in OPTIMIZE-1 Phase II clinical trial evaluating mitazalimab in combination with mFOLFIRINOX for the treatment of Pancreatic Cancer. OPTIMIZE-1 is an open-label, multicenter study that will enroll up to 67 patients at clinical sites in
Belgium andFrance . The company is expecting an interim safety readout in Q1 2022 and an interim efficacy readout in Q4 2022.
Shanghai Henlius Biotech Inc. (China ) reported that Alligator's partner program AC101 had entered into Phase II clinical trial.
FINANCIAL SUMMARY
July-
- Net sales,
SEK 3.3 million (0.0) -
Operating result,
SEK -37.7 million (-30.6) -
Result for the period,
SEK -37.2 million (-30.8) -
Earnings per share before and after dilution,
SEK -0.43 (-0.43) -
Cash flow for the period,
SEK -30.4 million (-32.7) -
Cash and cash equivalents, incl. interest-bearing securities,
SEK 79.3 million (137.0)
January-
- Net sales,
SEK 7.7 million (4.4) -
Operating result,
SEK -104.7 million (-110.2) -
Result for the period,
SEK -104.9 million (-108.8) -
Earnings per share before and after dilution,
SEK -1.23 (-1.52) -
Cash flow for the period,
SEK -24.0 million (42.6)
The full report is attached as PDF available on the company's website: https://alligatorbioscience.se/en/investors/financial-reports/
Conference call/webcast
Alligator will host a conference call today,
The conference call will be broadcast live on the web via the link: https://financialhearings.com/event/13657
Telephone number for the conference call is:
SE: +46856642692
US: +1 6319131422
PIN US: 47085846#
For further information, please contact:
Phone: +46 46-540 82 23
E-mail: jur@alligatorbioscience.com
This information is such information as
About
https://news.cision.com/alligator-bioscience/r/alligator-bioscience-ab--interim-report-january-september-2021,c3437219
https://mb.cision.com/Main/12681/3437219/1483944.pdf
https://mb.cision.com/Public/12681/3437219/920ca2f2bcccaf30.pdf
(c) 2021 Cision. All rights reserved., source